# Radiomic Signature as Predictive Marker of Response to Chemoradiation and Durvalumab in Stage III NSCLC.

> **NCT04364776** · — · UNKNOWN · sponsor: **Fondazione IRCCS Policlinico San Matteo di Pavia** · enrollment: 100 (actual)

## Conditions studied

- Lung Cancer
- Lung Cancer Stage III

## Interventions

- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT04364776
- **Lead sponsor:** Fondazione IRCCS Policlinico San Matteo di Pavia
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-15
- **Primary completion:** 2023-12-15
- **Final completion:** 2024-12-15
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2023-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04364776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04364776, "Radiomic Signature as Predictive Marker of Response to Chemoradiation and Durvalumab in Stage III NSCLC.". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04364776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*